Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer
Authors
Keywords
-
Journal
Biomolecules
Volume 10, Issue 12, Pages 1686
Publisher
MDPI AG
Online
2020-12-17
DOI
10.3390/biom10121686
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SETD3 acts as a prognostic marker in breast cancer patients and modulates the viability and invasion of breast cancer cells
- (2020) Nourhan Hassan et al. Scientific Reports
- High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
- (2019) Michael-Antony Lisio et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas
- (2019) Asako Kukita et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Histone methyltransferase KMT5A gene modulates oncogenesis and lipid metabolism of papillary thyroid cancer in�vitro
- (2018) Tian Liao et al. ONCOLOGY REPORTS
- Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines
- (2018) Eniko Papp et al. Cell Reports
- Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer
- (2017) Shinya Oki et al. Oncotarget
- Epigenetic therapy with inhibitors of histone methylation suppresses DNA damage signaling and increases glioma cell radiosensitivity
- (2017) Ozge Gursoy-Yuzugullu et al. Oncotarget
- miR-502 medaited histone methyltransferase SET8 expression is associated with outcome of esophageal squamous cell carcinoma
- (2016) Cuiju Wang et al. Scientific Reports
- SET8 expression is associated with overall survival in gastric cancer
- (2015) X.L. Shi et al. GENETICS AND MOLECULAR RESEARCH
- SET8 induces epithelial-mesenchymal transition and enhances prostate cancer cell metastasis by cooperating with ZEB1
- (2015) LIEJUN HOU et al. Molecular Medicine Reports
- Histone H4 Lys 20 methyltransferase SET8 promotes androgen receptor-mediated transcription activation in prostate cancer
- (2014) Lushuai Yao et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Discovery of a Selective, Substrate-Competitive Inhibitor of the Lysine Methyltransferase SETD8
- (2014) Anqi Ma et al. JOURNAL OF MEDICINAL CHEMISTRY
- Critical role of lysine 134 methylation on histone H2AX for γ-H2AX production and DNA repair
- (2014) Kenbun Sone et al. Nature Communications
- Dynamic Methylation of Numb by Set8 Regulates Its Binding to p53 and Apoptosis
- (2013) Gurpreet Kaur Dhami et al. MOLECULAR CELL
- Histone Lysine Methyltransferase SETD8 Promotes Carcinogenesis by Deregulating PCNA Expression
- (2012) M. Takawa et al. CANCER RESEARCH
- Histone lysine methylation and demethylation pathways in cancer
- (2010) Radhika A. Varier et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Ovarian Cancer Pathogenesis: A Model in Evolution
- (2009) Alison M. Karst et al. Journal of Oncology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started